X

Bharat Immunologicals & Biologicals Corporation Ltd. Stock Analysis

Small Cap
Evaluated by 260 users | BSE: 524663 | NSE: |
Pharmaceuticals & Drugs
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed -35.46%-22.71%45.96%15.71%21.63%9.12%-5.81%21.63%-8.96%-13.3%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 2.82.646.317320314612812434.883.7
Y-o-Y Gr. Rt.--10.2%1717.3%272.9%17.3%-27.9%-12.4%-3%-72%140.4%
Adjusted EPS (Rs.) -2.04-0.972.661.051.040.57-1.441.48-0.99-1.87
Y-o-Y Gr. Rt.-NANA-60.5%-1%-45.2%-352.6%NA-166.9%NA
Book Value per Share (Rs.) 4.663.696.569.729.219.578.139.678.687.1
Adjusted Net Profit -8.8-4.211.54.54.52.5-6.26.4-4.3-8.1
Net Op. Cash Flow (Rs. Cr.) -3.2-3531.4-11.97.8-9.4-172.5-32.1
Debt to Cash Flow from Ops -0.1601.3800.1-1.13-1.0100-1
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Bharat Immunologicals & Biologicals Corporation Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 45.6%-16.2%-13.2%140.4%
Adjusted EPS NA-212.5%NANA
Book Value per Share 4.8-5.1-4.4-18.2
Share Price 10.6% -4.6% 1.1% 284.5%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) -35.84-23.1751.7712.87116.04-16.2516.63-10.76-23.7
Operating Profit Margin (%) -134.04-153.9812.015.355.93.21-3.1510.33-22.78-11.14
Net Profit Margin (%) -309.77-163.7924.742.622.221.68-4.855.15-12.25-9.66
Debt to Equity 0.0300.240-0.03-0.210.27001.05
Working Capital Days 814843211888713011974159267
Cash Conversion Cycle 40341892216385546125153
Entity Percentage Holding
Promoters 59.25%
Non-Institutions 40.75%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Bharat Immunologicals & Biologicals Corporation Ltd.'s performance infers:

Bharat Immunologicals & Biologicals Corporation Ltd. earnings have declined by -212.5%, whereas share price has depreciated -4.6% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Bharat Immunologicals & Biologicals Corporation Ltd. share prices over the last 10 years. Here is what we found out:

Bharat Immunologicals & Biologicals Corporation Ltd. share price has depreciated 3% annually over the past ten years.

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.

BIBCOL’s principal mission is to save the

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.

BIBCOL’s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination. Since its inception, it has contributed significantly to the eradication of Poliomyelitis in the country through the National Immunization Program. BIBCOL is the pioneer in the field of polio vaccines, capturing 60% of total market share in India. The company has achieved a turnover of Rs.30.53 crores during the fiscal year 2005-2006 and earned a net profit of Rs.88.08 Lakhs. Based on the performance of the company and its world class WHO-cGMP certified infrastructure, highly skilled manpower and constant support from DBT, Government of India, BIBCOL is one among the top 20 Biotech companies in India, as revealed by recent market surveys.

Business area of the company:

The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh.

The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1,2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary moneky kidney cell culture. Each dose contains Poliovirus type 1 = 106.0Poliovirus type 2 = 105.0Poliovirus type 3 = 105.8The vaccine contains stabilizers and traces of antibiotics.Doses: 0.1 ml (two drops)Packing Size: 3 ml vial contains 20 doses of OPVStorage: Vaccine is potent if stored at -20oC for 2 years

The trivalent OPV manufactured by BIBCOL is of excellent quality and complies with the GMP requirements of Shedule M of Drugs & Cosmetics Act of Government of India.

Milestones:

  • 1989 - BIBCOL was established by Department of Biotechnology, Ministry of Science & Technology, Govt.of India as a Central Public Sector Unit and incorporated under the Company’s Act 1956.
  • 1989 - About 30 young scientists and technologists from the field of Microbiology, Immunology, Biotechnology, Biochemistry, Pharmaceutical Sciences and Biochemical Engineering were recruited by DBT and trained in the field of vaccine production and quality control in reputed institutes in India and a specialized training at the Institute of Poliomyelitis and Viral Encephalitis, Moscow, Russia
  • 1994- BIBCOL went public and the shares of the company were listed in Delhi, Mumbai and Kanpur stock exchanges
  • 1996 -The company started formulating OPV from bulk since January 1996
  • 1999 - The company acquired WHO-GMP certification
  • 2000- BIBCOL bagged an order from UNICEF as well as from Ministry of Health and Family Welfare, Govt.of India for a total of 170 million doses
  • 2001 - The company bagged another larger order of 270 million doses from UNICEF as well as from the Ministry of Health & Family Welfare, Govt.of India
  • 2004- Due to the extensive restructuring with in the company, BIBCOL achieved a turn over of Rs.53.25 crore during the fiscal year 2004-2005 and has earned a net profit of 132.44 lacs for the first time against the loss pf Rs.3.14 crore during the previous fiscal year 2003-2004
  • 2005 -For the first time, the company has signed a MoU with DBT for the fiscal year 2005-2006. The OPV plant at Chola, Bulandshahr has supplied about 1016 million doses of OPV to the National Immunization Program so far. During the year 2004-2005, 120 million doses were formulated and supplied to NIP, capturing nearly 60 percent of the total market share of polio vaccines in the country.
  • 2006 - The company has secured a place among the Top 20 Biotech companies in the country through its commendable performance.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback